» Articles » PMID: 32895522

A Framework for Designing Delivery Systems

Overview
Journal Nat Nanotechnol
Specialty Biotechnology
Date 2020 Sep 8
PMID 32895522
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

The delivery of medical agents to a specific diseased tissue or cell is critical for diagnosing and treating patients. Nanomaterials are promising vehicles to transport agents that include drugs, contrast agents, immunotherapies and gene editors. They can be engineered to have different physical and chemical properties that influence their interactions with their biological environments and delivery destinations. In this Review Article, we discuss nanoparticle delivery systems and how the biology of disease should inform their design. We propose developing a framework for building optimal delivery systems that uses nanoparticle-biological interaction data and computational analyses to guide future nanomaterial designs and delivery strategies.

Citing Articles

SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.

Cai Q, Guo R, Chen D, Deng Z, Gao J J Nanobiotechnology. 2025; 23(1):178.

PMID: 40050980 PMC: 11884119. DOI: 10.1186/s12951-025-03254-9.


Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors.

El-Sahli S, Manturthi S, Durocher E, Bo Y, Akman A, Sannan C ACS Pharmacol Transl Sci. 2025; 8(2):460-469.

PMID: 39974646 PMC: 11833720. DOI: 10.1021/acsptsci.4c00597.


Investigation on the Interaction of Dendritic Core Multi-Shell Nanoparticles with Human Red Blood Cells.

Krauss J, Georgieva R, Karabaliev M, Hackmann M, Rerkshanandana P, Chaiwaree S Nanomaterials (Basel). 2025; 15(3).

PMID: 39940163 PMC: 11820349. DOI: 10.3390/nano15030187.


Barcoded screening identifies nanocarriers for protein delivery to kidney.

Wang L, Zhou W, Chen H, Jia X, Zheng P, Jiang H Nat Commun. 2025; 16(1):899.

PMID: 39837887 PMC: 11751284. DOI: 10.1038/s41467-025-56257-3.


Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.